Ethic Inc. Purchases 9,856 Shares of Fresenius Medical Care AG (NYSE:FMS)

Ethic Inc. boosted its holdings in Fresenius Medical Care AG (NYSE:FMS - Free Report) by 25.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 49,286 shares of the company's stock after acquiring an additional 9,856 shares during the period. Ethic Inc.'s holdings in Fresenius Medical Care were worth $1,116,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also made changes to their positions in FMS. ABC Arbitrage SA acquired a new stake in Fresenius Medical Care during the 4th quarter valued at $4,215,000. OLD Mission Capital LLC bought a new position in Fresenius Medical Care in the fourth quarter worth about $3,545,000. Broyhill Asset Management acquired a new stake in Fresenius Medical Care in the fourth quarter worth $3,412,000. Northern Trust Corp raised its position in shares of Fresenius Medical Care by 45.9% during the 4th quarter. Northern Trust Corp now owns 362,190 shares of the company's stock worth $8,200,000 after buying an additional 113,953 shares in the last quarter. Finally, Marshall Wace LLP lifted its position in Fresenius Medical Care by 128.0% in the fourth quarter. Marshall Wace LLP now owns 129,581 shares of the company's stock worth $2,934,000 after purchasing an additional 72,740 shares during the period. Institutional investors and hedge funds own 8.37% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on FMS shares. Morgan Stanley reiterated an "underweight" rating on shares of Fresenius Medical Care in a report on Thursday. Truist Financial boosted their price objective on shares of Fresenius Medical Care from $25.00 to $30.00 and gave the stock a "hold" rating in a research note on Monday, May 12th. Finally, StockNews.com raised Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Fresenius Medical Care presently has an average rating of "Hold" and an average target price of $27.80.

Fresenius Medical Care Trading Up 1.1%

Shares of NYSE FMS traded up $0.31 during midday trading on Monday, hitting $29.09. The stock had a trading volume of 98,063 shares, compared to its average volume of 323,506. The company's 50-day simple moving average is $24.98 and its 200 day simple moving average is $23.73. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The firm has a market cap of $17.07 billion, a P/E ratio of 24.04, a price-to-earnings-growth ratio of 0.76 and a beta of 0.85. Fresenius Medical Care AG has a fifty-two week low of $17.93 and a fifty-two week high of $29.23.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.43 by $0.01. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The firm had revenue of $5.54 billion for the quarter, compared to analyst estimates of $4.71 billion. Research analysts anticipate that Fresenius Medical Care AG will post 1.51 EPS for the current year.

Fresenius Medical Care Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 23rd will be paid a $0.7871 dividend. This represents a yield of 1.9%. The ex-dividend date of this dividend is Friday, May 23rd. This is a boost from Fresenius Medical Care's previous annual dividend of $0.44. Fresenius Medical Care's dividend payout ratio is 49.11%.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.